Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.
This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
At the Dubois Memorial Lecture presented at ACR Convergence 2025, Shaun Jackson, MD, PhD, discussed the evolving understanding of the role of B cells in SLE.
Urine biomarkers have the potential to change how lupus nephritis is managed, serving as a noninvasive means of early detection, assessing treatment response and more.
Aydemir et al. examined the relationship between disease activity in rheumatoid arthritis (RA) and pain regulatory mechanisms of the central nervous system. They found that improvements in pain sensitivity were associated with reductions in disease activity in patients with RA after 12 weeks of treatment with disease-modifying anti-rheumatic drugs. This study underscores the importance of inflammatory and noninflammatory contributors to patient outcomes.
Lupus has always had a reputation for being a wild, unrestrained and enigmatic entity. In fact, the very name lupus comes from the Latin word for wolf, a gift from our Roman predecessors who saw a resemblance between lupus rashes and a wolf’s bite. Given the limitations of immunology back then, it is an incredibly…